Last reviewed · How we verify
NCT05864677: Cereb-POD
Cerebrolysin in Prevention of Postoperative Delirium in Cardiac Surgery
NA trial testing Cerebrolysin in Neurocognitive Disorders in 100 participants. Status unknown.
30 June 2024
Quick facts
| Lead sponsor | Medical University of Lublin |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 100 |
| Start date | 15 January 2023 |
| Primary completion | 30 June 2024 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across Poland |
Drugs / interventions tested
- Cerebrolysin — full drug profile →
Conditions studied
- Neurocognitive Disorders — all drugs for Neurocognitive Disorders →
- Surgery-Complications — all drugs for Surgery-Complications →
- Critical Illness — all drugs for Critical Illness →
- Brain Damage — all drugs for Brain Damage →
Sponsor
Medical University of Lublin
Who can join
Adults 18 to 90, any sex, with Neurocognitive Disorders or Surgery-Complications. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Postoperative delirium (POD) and postoperative neuropsychological dysfunction are frequently noted in critically ill patients undergoing elective or emergency surgery and treated in the intensive care unit (ICU). Delirium is a serious complication that prolongs hospital stay and contributes to poor outcomes and increased risk of death. The pathomechanisms of delirium are still not very well recognized and there are several theories that seem to explain it. The most important pathomechanisms of delirium are associated with cerebral ischaemia, disorders in acetylcholinergic system, disorders in neuronal plasticity and oxidative stress. Cerebrolysin, a mixture of various peptides obtained from the structural proteins of the pig's brain, possesses strong antioxidative and neuronal protective properties. Cerebrolysin is recommended to treat patients with dementia, after cerebral ischemia and after brain trauma. It has been documented that Cerebrolysin reduces the severity of secondary brain damage after ischemia, improving neuronal plasticity and then cognitive function, and reducing severity of oxidative stress. Based on these properties it can be speculated that Cerebrolysin may reduce the risk of postoperative delirium in patients undergoing elective surgery, which are associated with a high risk of postoperative delirium.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Effect of Cerebrolysin on Cognitive Function and Delirium in Coronary Artery Bypass Graft Patients.
Stadnik A, Jezierska M, Płotek W, Siwicka D, et al · · 2025 · PMID 40350671 · DOI 10.12659/msm.947864
Verify or expand the search:
- PubMed search for NCT05864677
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Cerebrolysin
Trials testing the same drug.
- NCT06339411 — Exploring Cerebrolysin in Late Thrombectomy for Stroke: Blood-brain Barrier Biomarkers and Imaging Insights · EARLY_PHASE1 · not yet recruiting
- NCT06677502 — Cerebrolysin in Critically Ill Patients With Delirium · NA · enrolling by invitation
- NCT05755997 — CERebrolysin In CADASIL · Phase 2 · active not recruiting
- NCT06070753 — A Prospective, Trial About Safety and Efficacy of Combined Treatment With Cerebrolysin in Acute Ischemic Hemispheric Str · NA · unknown
- NCT06052787 — Combined Cerebrolysin and Amantadine Sulfate Administration for Patients With Traumatic Brain Injury in the ICU · Phase 3 · completed
Other recruiting trials for Neurocognitive Disorders
Currently open trials in the same condition.
- NCT07526740 — Brain Stimulation and Cognitive Training for MCI · NA · recruiting
- NCT07418008 — The Liver Cirrhosis Cognitive Decline Scale (LiCCoS) · recruiting
- NCT07294963 — Impact of Lifestyle Interventions on Cognitive Decline in Non-alcoholic Fatty Liver Disease · NA · recruiting
- NCT06638710 — Efficacy and Safety of Oral Midazolam Used for the Delivery of Care in Elderly Patient With Neurocognitive Disorders and · Phase 2 · recruiting
- NCT07048002 — Interventions for Silent Brain Infarction and Perioperative Neurocognitive Disorders in Cardiovascular Surgery · NA · recruiting
Other Medical University of Lublin trials
Trials by the same sponsor.
- NCT07085286 — Perfusion Related Evaluation of Systemic and Renal Vulnerability to Events in CABG · not yet recruiting
- NCT06897436 — Characterization of Immune Cells and Their Secreted Cytokines in Endometriosis Patients · not yet recruiting
- NCT06516835 — Diluted and Undiluted Enteral Nutrition · NA · not yet recruiting
- NCT07182318 — Validation of the FIGO Nutrition Checklist in Pregnant Women · completed
- NCT06282666 — Lumbar ESPB in Hip Replacement Surgery · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05864677 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medical University of Lublin
- Last refreshed: 10 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05864677.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing